Non-Alcoholic Fatty Liver Disease: A Practical Guide [Farrell - Wiley - Blackwell]
calcActive())">
- ISBN/EAN
- 9780470673171
- Editore
- Wiley - Blackwell
- Formato
- Cartonato
- Anno
- 2013
- Pagine
- 324
Disponibile
125,00 €
Do you have patients referred to you suffering from NAFLD?
Are you looking for an expert guide to the latest in clinical management?
If so, this is the book for you, providing an expert and comprehensive analysis of NAFLD: what it is, why it happens, who is likely to suffer from it, and how to decide on the best management options for your patients.
This book focuses clearly on providing first-rate clinical guidance as to the assessment, diagnosis and treatment of patients in the clinical setting, based wherever possible on the latest evidence and scientific understanding of disease mechanisms. With each chapter fully revised and updated with the very latest in AASLD, EASL and Asia-Pacific guidelines, this second edition provides:
Four brand new chapters, including “NAFLD and cardiovascular risk factors” and “Non-invasive methods to determine severity of NAFLD/ NASH”
A clear overview on the causative mechanisms of NAFLD
Self-assessment via key points and multiple-choice questions throughout
The very latest in clinical drug trials
Analysis of NAFLD in relation to obesity, diabetes, high cholesterol and liver cancer
A consideration of NAFLD importance in Asia (particularly including Japan and China) and South America, as well as Europe and North America
NAFLD is a serious condition that is increasing in prevalence globally from year to year. Non-Alcoholic Fatty Liver Disease: A Practical Guide, is essential reading for all hepatologists and health professionals managing patients who have this condition.
Maggiori Informazioni
| Autore | Farrell Geoffrey C.; McCullough Arthur J.; Day Christopher P. |
|---|---|
| Editore | Wiley - Blackwell |
| Anno | 2013 |
| Tipologia | Libro |
| Lingua | Inglese |
| Indice | 1 What is non-alcoholic fatty liver disease (NAFLD), and why is it important? 1 Geoffrey C. Farrell, Arthur J. McCullough, and Christopher P. Day 2 NAFLD in the community, 17 Leon A. Adams 3 Pathology of NAFLD, 27 Elizabeth M. Brunt and David E. Kleiner 4 The natural history of NAFLD, 37 Paul Angulo 5 Emerging concepts on the pathogenesis of non-alcoholic steatohepatitis (NASH), 46 Isabelle A. Leclercq 6 Diabetes and NAFLD: why is the connection important? 62 Elisabetta Bugianesi 7 NAFLD and cardiovascular risk factors: implications for vascular disease, 71 Giovanni Targher 8 A primary care perspective of fatty liver: diagnosis, management, prescribing, and when to refer, 84 Shivakumar Chitturi and Geoffrey C. Farrell 9 Imaging of NAFLD, 93 Takeshi Yokoo, An Tang, and Claude B. Sirlin 10 Non-invasive methods to determine the severity of NAFLD and NASH, 112 Vincent Wai-Sun Wong and Henry Lik-Yuen Chan 11 Fatigue, quality of life, and psychosocial issues for people with NAFLD, 122 Julia L. Newton and James Frith 12 Physical activity and cardiovascular fi tness in patients with NAFLD: clinical importance and therapeutic implications, 132 Ingrid J. Hickman, Graeme A. Macdonald, and Nuala M. Byrne 13 NAFLD, obesity, and bariatric surgery, 149 Philippe Mathurin 14 Genetic predisposition to NAFLD and NASH: implications for pathogenesis, diagnosis, prevention, and management, 157 Quentin M. Anstee, Ann K. Daly, and Christopher P. Day 15 NAFLD in children, 171 Ariel E. Feldstein 16 The pointy end of the NAFLD iceberg: cirrhosis, portal hypertension, and liver failure, 182 Jonathon W. Schwake, Dawn M. Torres, and Stephen A. Harrison 17 Non-alcoholic fatty liver disease, hepatocellular cancer, and other cancers, 192 Janine Graham and Helen L. Reeves 18 NAFLD in Chinese and South Asian people, 206 Jia-Horng Kao, Deepak Amarapurkar, and Jian-Gao Fan 19 Non-alcoholic fatty liver disease in Japan, 217 Takeshi Okanoue, Kohichiroh Yasui, and Yoshito Itoh 20 Non-alcoholic fatty liver disease in South America and Hispanic people, 228 Helma Pinchemel Cotrim and Carla Daltro 21 Alcohol in non-alcoholic fatty liver disease: an oxymoron or a new standard of care?, 234 Achuthan Sourianarayanane, Srinivasan Dasarathy, and Arthur J. McCullough 22 Dietary factors in the pathogenesis and care of patients with fatty liver disease, 248 Giulio Marchesini, Rebecca Marzocchi, Anna S. Sasdelli, Cristiana Andruccioli, and Silvia Di Domizio 23 Metabolic factors and steatosis in patients with hepatitis B and C, 260 Francesco Negro 24 Drug therapy for NASH: insulin-sensitizing agents (metformin and thiazolidinediones), 271 Mohammad S. Siddiqui and Arun J. Sanyal 25 Hepatoprotectants against fatty liver disease: antioxidants, ursodeoxycholic acid, and herbal medicines, 284 Anne Catherine Bürgi and Jean-François Dufour 26 Lipid modifiers and NASH: statins, ezetimibe, fibrates, and other agents, 293 Giovanni Musso, Federica Molinaro, Elena Paschetta, Roberto Gambino, and Maurizio Cassader Index, 308 |
Questo libro è anche in:
